SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 16778
  • 2
    Abrams P, Artibani W, Cardozo L, Dmochowski R, Van Kerrebroeck P, Sand P. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2006; 25: 293
  • 3
    Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6 (Suppl. 11): S5749
  • 4
    Wagner TH, Hu TW, Bentkover J et al. Health-related consequences of overactive bladder. Am J Manag Care 2002; 8 (Suppl. 19): S598607
  • 5
    Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 130615
  • 6
    Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 7606
  • 7
    Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 32736
  • 8
    Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999; 161: 180912
  • 9
    Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000; 95: 71821
  • 10
    Gleason DM, Susset J, White C, Munoz DR, Sand PK. Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Urology 1999; 54: 4203
  • 11
    MacDiarmid SA, Anderson RU, Armstrong RB, Dmochowski RR. Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies. J Urol 2005; 174: 13015
  • 12
    Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 2005; 95: 5806
  • 13
    Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 46470
  • 14
    Cardozo L, Heßdörfer E, Milani R et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008; 102: 11207
  • 15
    Karram MM, Toglia MR, Serels SR et al. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009; 73: 148
  • 16
    Cardozo L, Serels S, Hessdörfer E, Milani R, Huang M. Solifenacin improves urgency in OAB. Results from the SUNRISE and VENUS Studies. Presented at 4th ICI Congress. Paris, France, July 2008 Poster 003
  • 17
    Chancellor MB, Zinner N, Whitmore K et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther 2008; 30: 176681
  • 18
    Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther 2006; 28: 193546
  • 19
    Kaufman L, De Groote P, Merckx L, Decoster M, Dolhain J, Smets J. Do physicians and patients with OAB have the same perception of treatment benefit from solifenacin? Results of the Belgian Evaluation of Solifenacin (EOS) trial. Eur Urol Suppl 2007; 6: 204, Abstract 725
  • 20
    Michel M, Wetterauer U, Vogel M, De La Rosette J. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. Drug Saf 2008; 31: 50514
  • 21
    Chapple C, Fiala R, Gorilovsky L et al. The STAR study: analysis of symptom severity and treatment response in overactive bladder. Presented at 21st EAU Congress, Paris, France, April 2006 Poster 380
  • 22
    Cardozo L, Avdoshin V, Wolski Z, Pavlik I, Sofras F et al. Overactive bladder syndrome – is a request for a dose increase indicative of more severe symptoms? Results from a randomised, double-blind, placebo-controlled, rising-dose study of solifenacin (SUNRISE). Presented at 32nd IUGA Congress, Cancun, Mexico, June 2007 Poster 116
  • 23
    Chapple CR, Artibani W, Cardozo LD et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005; 95: 33540
  • 24
    Artibani W. Outcomes in overactive bladder treatment: patient perception – a key to success. Eur Urol Suppl 2007; 6: 1722